Vincristine and irinotecan in children with relapsed hepatoblastoma: a single-institution experience.
OBJECTIVE
This study was to determine the efficacy of vincristine and irinotecan in children with relapsed hepatoblastoma (HB).


METHODS
A total of 10 patients with relapsed HB were enrolled. Three patients were excluded. Patients received irinotecan 50 mg/m(2)/day, day 1-5 and vincristine 1.5 mg/m(2)/day, day 1, repeated every 3 weeks. The maximum cycles were eight. Reevaluation of tumor was performed every two cycles. The primary outcome was the rate of complete resection. Secondary outcomes were event-free survival (EFS) and overall survival (OS).


RESULTS
Of the seven patients assessable for response, one patient with normal AFP level showed a progressive disease and withdrew. He finally died 6 months later. Four had PR, all of them underwent a second surgery and achieved complete resection. Two patients had SD, one patient relapsed 6 months after orthotopic liver transplantation and died, the other one undergoing surgery had micro margin positive, he relapsed again but alive. The rate of complete resection was 71.4% (including orthotopic liver transplantation). The 2-year EFS and OS for the whole group were 57.1% (95% CI, 12.7% to 34.2%) and 71.4% (95% CI, 16.39% to 37.4%), respectively.


CONCLUSIONS
The combination of irinotecan and vincristine has a significant antitumor activity and acceptable toxicity in children with relapsed HB.
1Department of Pediatric Hematology and Oncology, the First Hospital of Jilin University, Changchun, Jilin, China.
Yu-tong
YT
Zhang
Li-hua
LH
Feng
Xiao-dan
XD
Zhong
Li-zhe
LZ
Wang
Jian
J
Chang
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002675:Child, Preschool; D018572:Disease-Free Survival; D018197:Hepatoblastoma / Q000401:mortality / Q000628:therapy; D006801:Humans; D007223:Infant; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy; D016031:Liver Transplantation; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000628:therapy; D015996:Survival Rate; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D000077146:Irinotecan; D002166:Camptothecin
children; hepatoblastoma; irinotecan; relapsed hepatoblastoma